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ABSTRACT
Objectives: Radioiodine ablation for the treatment of thyroid cancer is
traditionally performed after preparing patients by inducing hypothyroid-
ism. Exogenous stimulation of thyroid-stimulating hormone (TSH) using
recombinant human TSH (rhTSH) avoids hypothyroidism and hastens the
clearance of radioiodine from the patient. These advantages are achieved
without jeopardizing the success rate of remnant ablation. An economic
analysis was performed to place the increased acquisition cost of rhTSH in
the context of the health beneﬁts achieved and the earlier discharge from
radioprotection.
Methods: Markov modeling, using 17 individual weekly cycles, was used
to assess the incremental cost per quality-adjusted life-year (QALY) asso-
ciated with exogenous stimulation. Clinical inputs were largely sourced
from a multicenter, randomized, controlled trial comparing remnant abla-
tion success after either rhTSH or hypothyroid preparation. The model
applied Canadian unit costs, taking a societal perspective. Additional costs
associated with rhTSH were considered in the context of the clinical
beneﬁts and cost offsets. These included avoidance of hypothyroidism,
increased work productivity, earlier administration of ablation after
surgery, and earlier discharge from the radio-protective ward because of
faster radioiodine clearance following rhTSH preparation. The model
duration avoided the need for discounting.
Results: The additional beneﬁts of rhTSH (0.0576 QALY) are obtained
with an incremental cost of CDN$87, generating an incremental cost per
QALY of CDN$1520. Deterministic one-way and two-way sensitivity
analyses demonstrated the result to be robust.
Conclusions: The use of rhTSH before radioiodine ablation represents a
reasonable allocation of costs, with the beneﬁts to patients, hospitals, and
society as a whole, obtained at modest cost.
Keywords: cost-effectiveness, hypothyroid, rhTSH, thyroid cancer.
Introduction
Surgical intervention using thyroidectomy followed by 131I radio-
iodine ablation remains the standard treatment for stages 3 and
4, as well as many patients with stages 1 and 2 differentiated
thyroid cancer [1]. The aim of the radioiodine ablation is to
destroy thyroid remnants through selective uptake of iodine into
the thyroid tissue. This is traditionally achieved by rendering
patients hypothyroid by denying thyroid hormone replacement
therapy with thyroxine (T4) from thyroidectomized patients for
several weeks before ablation. Although inducement of hypothy-
roidism elevates serum thyroid-stimulating hormone (TSH) such
that radioiodine uptake by remnants is optimal [2], it is associ-
ated with signiﬁcant morbidity. Commonly encountered prob-
lems include severe lethargy and fatigue, cognitive problems,
constipation, cold intolerance, and depression in the young, and
ataxia, ambulation problems, falls, and cardiac and renal prob-
lems in the elderly. The severity of symptoms often translates to
an inability to perform normal activities [3–6]. Additionally,
there is a need to provoke a threshold level of hypothyroidism
before the patient can be treated with radioiodine ablation (TSH
typically >25–30 mU/L), which in practice can take anywhere
from 3 to 8 weeks to achieve after surgery. This variability causes
scheduling problems for hospital administrators, particularly
where access to radio-protective beds is limited.
Alternatively, exogenous stimulation of TSH using recombi-
nant human TSH (rhTSH) allows patients to commence thyroid
hormone replacement therapy immediately after thyroidectomy,
and therefore avoid hypothyroidism. Additionally, this offers
hospitals and patients clarity with respect to scheduling radioio-
dine ablation. Investigators have shown that exogenous rhTSH
can sufﬁciently stimulate 131I uptake in thyroid remnants to result
in successful remnant ablation [7–10]. Additionally, a multi-
center, randomized, controlled trial has demonstrated 100% suc-
cessful ablation after 8 months of follow-up according to a
predeﬁned criterion (i.e., no visible thyroid bed activity or <0.1%
131I uptake), regardless of stimulation method [11,12]. A second-
ary criterion for successful ablation (a stimulated serum thyro-
globulin level of <2 ng/ml 8 months after ablation) favored the
euthyroid group (96 vs. 86%) [11]. Furthermore, the same study
demonstrated considerable quality-of-life beneﬁts associated
with exogenous rhTSH stimulation, with a signiﬁcant difference
in the change between baseline and ablation between study arms
in ﬁve of the eight domains measured (P < 0.05) [11,12].
In addition to an improvement in quality of life, exogenous
stimulation results in faster clearance of 131I from the body after
radioiodine ablation, presumably by avoiding the renal impair-
ment associated with hypothyroidism [12–14]. This has trans-
lated to a shorter time required in the radio-protective ward in
several hospitals, and less overall radiation exposure to the
patient [15,16].
Exogenous stimulation with rhTSH, however, is associated
with an additional acquisition cost relative to endogenous stimu-
lation. To contextualize the increased cost, an economic analysis
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was performed capturing all costs accruing in the period between
thyroidectomy and recovery from ablation, as well as the differ-
ences in quality of life associated with its use. In doing so, the
value for money can be accurately examined.
The current model, an adaptation of an earlier German-based
model [17], relates speciﬁcally to the Canadian setting, capturing
local management of thyroid cancer patients. In addition, some
Canadian institutions allow radioiodine ablation with up to
150 mCi to be performed as an outpatient service, provided the
patient meets certain criteria [18]. This is notably different to the
radiation regulations applicable in the previous model [17], and
therefore this scenario is also investigated here.
Methods
Model Structure
Economic modeling was undertaken to demonstrate the value of
rhTSH before ablation in terms of the extra costs relative to
patient beneﬁts. These beneﬁts were expressed in units of quality-
adjusted life-years (QALYs) using “utility weights” from 0
(death) to 1 (perfect health) derived from SF-36 data, a method
common in health economics. By using a common metric, the
value for money of rhTSH can be compared against other health
technologies. A societal approach, rather than that of a single
payer, ensured that all relevant costs and outcomes were captured.
A Markov model was used to compare the expected costs and
outcomes of patients with low-risk thyroid cancer who would
nevertheless require radioiodine ablation, and who are prepared
with exogenous stimulation (with rhTSH), against those pre-
pared with endogenous stimulation (with hypothyroidism result-
ing from the withdrawal or withholding of thyroid hormone).
Markov modeling is a popular methodology in health economics
because of its ability to follow patients as they move between
health states over time.
The model was run for a total of 17 cycles of 1 week in
length. The 17-week model duration is a departure from the
previous German version [17] which took a lifetime perspective
and encompassed the theoretical advantage of a reduction in
secondary malignancies, a potential beneﬁt of radioablation with
rhTSH because of less total body radiation exposure. This sim-
pliﬁcation was motivated by the lack of inﬂuence the secondary
malignancies had on the cost-effectiveness results [17]. Here, a
shorter-term focus reduces uncertainty associated with long-term
extrapolation, while still capturing all cost and outcome differ-
ences between thyroidectomy and recovery from ablation.
The model relates only to the treatment of low-risk,
radioablation-requiring, thyroid cancer patients similar to those
in the pivotal trial, which included patients with a T2, N0/N1,
M0 or a T1, N1, M0 classiﬁcation [12]. Patients with distant
metastases detected any time up to, and including, the post-
ablation scan were excluded from the model.
Four discreet health states were modeled in each of the two
arms (Table 1). Following thyroidectomy, patients receive either
exogenous rhTSH (Thyrogen, Genzyme Corporation, Cam-
bridge MA) and remain euthyroid, or undergo a period of
hypothyroidism induced by withholding TSH to raise their serum
TSH. All patients receive thyroid replacement therapy following
ablation. A schematic of the model is presented in Figure 1.
A half-cycle correction was appropriately omitted on the basis
that the model structure is such that individuals cannot move
between health states during either the ﬁrst or last cycle of the
model.
Costs and outcomes were accrued at the end of each cycle,
depending on the health state of the individual at that point in
time. For simplicity, neither costs nor outcomes were subject to
discounting, as the model duration is less than 1 year.
The analysis of the model included a number of sensitivity
analyses aimed at testing the impact of key assumptions/areas of
potential uncertainty, and to better understand themain drivers of
the results. Note that the inputs required to reasonably conduct a
probabilistic sensitivity analysis were not available for use.
The model as a whole was subject to internal review by a
health economist not directly involved in the project. All inputs
and calculations were checked. No clinical validation process
was required because of clinical success being assumed in both
arms of the model. Nonetheless, the Markov trace was examined
to ensure logical movement of the cohort from one health state to
another in each arm over the total duration of the model.
Clinical Inputs
Clinical inputs were sourced primarily from the pivotal multi-
center, randomized, controlled trial [11,12] supplemented with
information from the published literature.
Table 1 Description of health states
Health state Description
Preablation Patient has received successful thyroidectomy and is
undergoing a waiting period before ablation (1 week in
the euthyroid arm, and between 2 and 7 weeks in the
hypothyroid arm)
Ablation Patient undergoes radioiodine ablation procedure (1 week
comprising hospitalization and brief recovery period)
Postablation A recovery period following ablation in which utility
weights remain lower than complete recovery.
Postablation is divided into two periods.The ﬁrst
period has a lower utility than the second, so as to
capture a gradual recovery to the well health state
(two sequential 4-week periods)
Well Patient has recovered from thyroidectomy and ablation
(7 weeks in the euthyroid arm, and between 1 and 6
weeks in the hypothyroid arm)
Figure 1 Simpliﬁed schematic of the model structure.
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The time spent in the model was quality adjusted using utility
weights. Utility weights for the pre- and postablation health
states that differ between the arms of the model were obtained
from the pivotal controlled clinical trial. The SF-36 trial data [12]
were transformed into utility weights using the SF-6D method
[19] (Fig. 2). Table 2 lists the various utility weights, while
Figure 2 presents a visual summary of the utility weights associ-
ated with each of the health states.
Quality-of-life differences between the two stimulation
methods are well supported by the pivotal trial data [12]. In the
rhTSH-stimulated group, the SF-36 score increased from baseline
in seven of the eight domains by the time of ablation; in the
hypothyroid group, however, the SF-36 scores declined in seven
of the eight domains. The change from baseline was signiﬁcantly
different between groups in ﬁve of the eight domains (P < 0.05).
This implies that hypothyroid patients felt worse weeks later
(before ablation) than they had immediately after surgery—a
ﬁnding in keeping with clinical observation. Similar results were
previously reported for rhTSH in the diagnostic setting, with a
signiﬁcant difference in all eight domains of the SF-36
(P < 0.0001) [20].
As described previously, clinical success of ablation was unre-
lated to preparation method. The model assumed successful
ablation in all patients, according to the predeﬁned criterion of
the pivotal trial [12]. As in previous modeling [17], there was
assumed to be no difference in longer-term recurrence rates. This
has since been conﬁrmed in long-term follow-up of the patients
who took part in the pivotal randomized, controlled trial [21,22].
Potential adverse events were not included in the economic
model. Although a number of common adverse events such as
headache, fatigue, vomiting, and dizziness do occur in clinical
practice, these are usually transient and have little if any impact
on either quality of life or on cost. Rarely, rhTSH may cause a
serious problem such as swelling of an unrecognized brain
metastasis, although this can usually be prevented by proper
screening because patients with distant metastasis are not eligible
for rhTSH use.
Resource Use and Cost Inputs
Canadian resource use and unit costs were sourced with a soci-
etal perspective (see Table 3). The most up-to-date costs were
sourced in all instances, with all costs as published in either 2007
or 2008. It is not possible, however, to state with certainty the
cost year of the analysis as the information to do so was not
consistently available from these sources.
Figure 2 Health-related quality of life (SF-6D)
over time.
Table 2 Clinical inputs included in the economic model
Input
Exogenously
stimulated
(rhTSH) arm
Endogenously
stimulated
(hypothyroid) arm Notes Source
Thyroid cancer treatment
Radioiodine ablation success rate 100% 100% <0.1% Uptake in thyroid bed at 8 months
post-ablation
Pacini et al. [12]
Utility weights (annualized)
Preablation 0.714 0.548 SF-6D data derived from week 4 SF-36 data Pacini et al. [12]
Ablation 0.614 0.448 Preablation—0.1 Assumption
0–4 weeks postablation 0.712 0.637 SF-6D results derived from 1-month postablation
SF-36 data from pivotal trial
Data on ﬁle (Genzyme
Corporation)
4–8 weeks postablation 0.856 0.819 Average of “0–4 weeks postablation” and “well” Assumption
Well 1.00 1.00 Conventional value attributed to perfect health Convention
rhTSH, recombinant human thyroid-stimulating hormone; SF-36, short-form 36; SF-6D, short-form 6 dimension.
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Note that the cost of the low-iodine diet recommended before
radioiodine ablation was not included as it is common to both
arms and does not impact on the results.
The model captured the difference in time spent in the radio-
protective ward on the basis of faster clearance of 131I from the
body after radioiodine ablation following exogenous stimulation
[12–14,23]. A survey was conducted for this study among clini-
cians practicing in Canada (n = 24, treating 1884 patients) to
estimate the time spent in radio-protective conditions by endog-
enously stimulated patients. The most common lengths of stay in
the radio-protective ward in the survey were 1 day (28.45%), 2
days (40.78%), and 3 days (26.50%), with an average of 2.05
days across all survey respondents when the results were
weighted by the number of patients treated by each respondent.
On the basis of the 35% lower dose of radiation to the blood in
exogenously stimulated patients [12], the model assumed the
duration of hospitalization was, on average, one-third less in that
arm of the model (1.37 vs. 2.05 days). Although there are no data
to speciﬁcally support this assumption, it is in keeping with
estimates reported elsewhere [15,16]. Furthermore, there is no
expectation that the Canadian experience would be any different
as patients in Canada are typically discharged soon after the
period of isolation is lifted for ﬁnancial reasons. In institutions
permitting radioiodine ablation to be performed on an outpatient
basis, this cost offset will not apply. On this basis, a sensitivity
analysis was performed to investigate the cost-effectiveness in
such a situation.
The same survey was used, again by calculating a weighted
average, to determine the current interval between thyroidec-
tomy and ablation for endogenously stimulated patients in
Canada, as the pivotal trial could not be relied upon to give a
reliable estimate for the Canadian perspective. The model used
these survey results to account for variation between patients
(Table 4). The temporary use of triiodothyronine (T3) during this
pre-ablation period was not included in the economic model as
this was used for greater than 50% of treated patients by only 6
of the 24 clinicians in the survey. Furthermore, the pivotal clinical
trial did not represent the situation where T3 was used. With
respect to exogenously stimulated patients, radioiodine ablation
was assumed to occur closer to the time of thyroidectomy. This
assumption was based on clinical opinion that ablation would
occur earlier because: 1) time to elevate TSH levels endogenously
is not required when exogenous stimulation is provided; and 2)
timely ablation of any cancer remnants to reduce the risk of
spread or recurrence is an important clinical aim, although this
is controversial with respect to low-risk patients with well-
differentiated thyroid cancer. Nonetheless, at least a week is
typically required for adequate recovery from thyroidectomy.
A number of investigators reported reduced productivity and
increased absenteeism in the hypothyroid state compared with
the euthyroid state [3–6]. Similar to the earlier model [17], and
based on the literature [12], a 50% reduction in the number of
work days lost for exogenously stimulated patients relative to
endogenously stimulated patients was applied. The difference is
particularly important, as thyroid cancer typically affects people
in the prime of their productive work lives [24]. The model
adopted a friction cost method [25] for calculating the impact
this has on the economy’s productivity by assuming that only
80% of productivity is lost with absence from work with the
remainder made up upon return to work or by coworkers. This
assumption is based on Koopmanschap et al. [26], which esti-
mated that, in the case of short-term absences from work, a 10%
decrease in labor time leads to an 8% fall in production. This is
tested in the sensitivity analyses. Because a societal perspective is
adopted, the model acknowledges the productive output of all
Table 3 Unit costs incorporated into the economic model
Resource Unit cost ($) Remarks Source
Ablative dose of radioiodine (131I) to treat thyroid cancer
(post-thyroidectomy)
1424.00 OCCI,August 2007
Whole-body scan using radioiodine 297.25 Inclusive of an associated
$50.50 physician fee
London Health Science Centre,August 2007
One day of hospital (inpatient) for patients receiving
radioiodine ablation
1000.00 London Health Science Centre,August 2007
Visit to specialist (radiation oncologist)—initial assessment 83.25 OHIP Schedule of Physician Services,April 2008
Visit to specialist (radiation oncologist)—medical-speciﬁc
reassessment
45.90 OHIP Schedule of Physician Services,April 2008
Visit to general practitioner—general assessment 61.00 OHIP Schedule of Physician Services,April 2008
Visit to general practitioner—general reassessment 30.70 OHIP Schedule of Physician Services,April 2008
TSH quantation 14.48 OHIP Schedule of Beneﬁts for Laboratory Services,April
2008
Serum thyroglobulin count 20.68 OHIP Schedule of Beneﬁts for Laboratory Services,April
2008
Tg antibody test 15.00 Pak Cheung Chan, chief biochemist, Sunnybrook Health
Science Centre, personal communication
Average daily wage 146.92 Statistics Canada, June 2007
Daily T4 drug cost (100 mg) 0.03 Cost of Eltroxin used ODB formulary,August 2007
rhTSH (two ampoules of Thyrogen®) 1324.00 ODB formulary,August 2007
A further cost incurred by patients is a low-iodine diet, although this has been excluded on the basis that it is equal in both arms.
131I, iodine-131; OCCI, Ontario Case Costing Initiative database; ODB, Ontario Drug Beneﬁt; OHIP, Ontario Health Insurance Plan; rhTSH, recombinant human thyroid-stimulating hormone;
T4, thyroxine;Tg, thyroglobulin;TSH, thyroid-stimulating hormone.
Table 4 Distribution of time spent between thyroidectomy and ablation
in the endogenously stimulated patient group
Duration of time
between thyroidectomy
and ablation
Proportion of
patients estimated
in clinician survey (%) Remarks
Less than 3 weeks 0.90 Assumed to be 2 weeks
for all patients
3 weeks 6.48
4 weeks 12.50
5 weeks 10.85
6 weeks 21.15
Greater than 6 weeks 48.12 Assumed to be 7 weeks
for all patients
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individuals by valuing the productive time lost of all, regardless
of employment status. This was achieved by using the average
Canadian wage rate as a proxy for the productivity loss. That is,
the average daily wage is multiplied by 80%, without adjustment
for workforce participation and unemployment rates, to capture
the magnitude of the loss. It is acknowledged, however, that the
inclusion of productivity loss in the model risks double-counting
a portion of the productivity loss, because the SF-36 includes two
dimensions related to the impacts upon professional life. Unfor-
tunately, the extent of any double-counting is unknown and
cannot be accounted for. It should be noted, however, that the
friction cost method ensures the impact of double-counting is
minimized relative to other methods, such as the human capital
approach, because it generates a lower estimate of the loss of
productivity.
The rhTSH cost used in the model was based on a daily
intramuscular injection dose of 0.9 mg over a 2-day period
before radioiodine ablation. There is no requirement for moni-
toring following an rhTSH injection. All other costs associated
with administration were included in the costs applied to each
health state, as shown in Table 5.
Results
The results of the economic model are presented in Table 6, with
the base case relating to Canada in toto, and the primary sensi-
tivity analysis relating to the speciﬁc situation where radioiodine
is administered as an outpatient service. The remaining determin-
istic one-way and two-way sensitivity analyses are presented in
Figure 3.
Note that a one-way deterministic sensitivity analysis aimed
at examining the impact of a change to the number of productive
days lost because of ablation shows rhTSH preparation domi-
nating exogenously prepared stimulation. By using alternative
values from LeClere et al. [4] (1 day in the rhTSH arm, and 14.6
days in the endogenously stimulated arm), rhTSH preparation is
shown to save an average of $854.59 per patient. This result is
discussed in greater details below.
Table 5 Costs applied per health state in the economic model
Resource
Unit
cost ($)
Resources consumed,
exogenously stimulated
(rhTSH) arm
Resources consumed,
endogenously stimulated
(hypothyroid) arm
Cost per health state,
exogenously stimulated
(rhTSH) arm ($)
Cost per health state,
endogenously stimulated
(hypothyroid) arm ($)
Preablation
T4 thyroid hormone replacement therapy 0.03 7 — 0.23 —
TSH test 14.48 1 1 14.48 14.48
Tg test 20.68 1 1 20.68 20.68
Tg antibody test 15.00 1 1 15.00 15.00
Specialist visit—initial consultation 83.25 1 1 83.25 83.25
Specialist visit—repeat consultation 45.90 1 1 45.90 45.90
GP visit—general assessment 61.00 1 — 61.00 —
GP visit—general reassessment 30.70 1 — 30.70 —
Productivity loss 117.54 5.5 11 646.47 1292.94
rhTSH 1324.00 1 — 1324.00 —
Total cost of preablation 2241.71 1472.25
Ablation
131I ablation 1424.00 1 1 1424.00 1424.00
T4 thyroid hormone replacement therapy 0.03 7 — 0.23 —
Hospitalization in radio-protective ward 1000.00 1.37 2.05 1366.67 2050.00
Specialist visit—repeat consultation 45.90 2 2 91.80 91.80
Whole-body scan 297.25 1 1 297.25 297.25
Total cost of ablation 3179.95 3863.05
Post-ablation
T4 thyroid hormone replacement therapy 0.03 56 56 1.84 1.84
Specialist visit—repeat consultation 45.90 1 1 45.90 45.90
Total cost of postablation 47.74 47.74
Well
T4 thyroid hormone replacement therapy 0.03 14.77 49 1.61 0.48
Total cost of “well” 1.61 0.48
Total cost 5471.00 5383.52
131I, iodine-131; GP, general practitioner; rhTSH, recombinant human thyroid-stimulating hormone;T4, thyroxine;Tg, thyroglobulin;TSH, thyroid-stimulating hormone.
Table 6 Results of the base case and primary sensitivity analyses
Parameter
Exogenously
stimulated
(rhTSH) arm
Endogenously
stimulated
(hypothyroid) arm Incremental difference
Canada-wide:
Average cost incurred, per patient ($) 5,471 5,384 87
Average total QALY over course of model, per patient 0.2808 0.2232 0.0576
ICER $1,520 per QALY gained
Where ablation performed as outpatient, so no time spent in radio-protective ward:
Average cost incurred, per patient ($) 4,104 3,334 771
Average total QALY over course of model, per patient 0.2808 0.2232 0.0576
ICER $13,391 per QALY gained
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; rhTSH, recombinant human thyroid-stimulating hormone.
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Discussion
The economic model demonstrates that the additional health
beneﬁts of using rhTSH in preparation for radioiodine ablation
are obtained with minimal incremental cost to society ($87 per
patient). This incremental cost is modest when considered rela-
tive to the total cost of the initial surgical and radio-ablative
treatment of thyroid cancer. Cost offsets associated with use of
rhTSH, including earlier discharge from radio-protective care
and a reduction in the number of productive days lost because
of symptoms of hypothyroidism, drive the low cost. The modest
net cost of exogenous stimulation must be considered in the
context of the health beneﬁt it provides. Avoiding hypothyroid-
ism by using exogenous stimulation results in a substantial
improvement in patient quality of life, translating to an incre-
mental beneﬁt of 0.0576 QALY over a 17-week period (or one-
third of a year). The incremental cost and beneﬁt generate an
incremental cost-effectiveness ratio (ICER) of $1520/QALY. In
Canada, new health-care interventions are almost universally
accepted if the cost/QALY is less than $20,000, and are also
considered to be fundable if the cost/QALY lies between
$20,000 and $100,000 [27]. The use of rhTSH, therefore, rep-
resents a highly cost-effective technology (i.e., the additional
beneﬁts to the patient and society are procured for an accept-
able net cost).
The sensitivity analyses demonstrate the base case result and
conclusions drawn are robust. One-way sensitivity analyses indi-
cate the model is most sensitive to the difference in time spent in
the radio-protective ward. The primary sensitivity analysis indi-
cates an ICER of $13,391 when patients receive their radioiodine
as outpatients, that is, with no difference in the time spent under
radio-protective conditions, although patients are usually iso-
lated at home for 48 hours. In this situation, the ICER remains
below the $20,000 threshold [27]. The model is also sensitive,
albeit less so, to the difference in the number of productive days
lost. Similarly, reducing the length of the pre-ablation health state
to 3 weeks for all patients in the endogenously stimulated arm
results in only a modest increase in the ICER ($2678). This may
be more indicative of the result in those institutions that tempo-
rarily use T3 to shorten the period of hypothyroidism, albeit
without the inclusion of the T3 cost, which would further reduce
the ICER. A two-way sensitivity analysis considered the simul-
taneous impact of entirely removing both the difference in time
spent in the radio-protective ward and productive days lost. This
generated an ICER of less than $25,000/QALY. Even under these
extreme assumptions, therefore, exogenous stimulation using
rhTSH remains acceptable value for money [27].
In addition to the health beneﬁts to the patient, the produc-
tivity beneﬁts are also important to broader society, and warrant
further discussion. Data from the diagnostic follow-up setting are
useful in that they are free of the inﬂuence surgery or ablation per
se may have on productive capacity, that is, they are likely
because of hypothyroidism alone. Estimates of work days lost in
the diagnostic setting range from 11 to 13 days [4–6]. Of these,
one study [4] reporting paired data for a subgroup of patients
who received both stimulation methods, showed a mean of 14.6
days lost in the hypothyroid group, and 1.0 day for the rhTSH
group (P < 0.0001). There are no comparative published data
available in the ablation setting, although the duration and inten-
sity of hypothyroidism are similar to the diagnostic setting. The
pivotal trial similarly fails to provide insight, instead reporting
that 15.6% of those rendered hypothyroid experienced a marked
reduction in their ability to perform normal activities compared
with 8.6% in the rhTSH arm [12]. This differential formed the
basis of the 50% difference applied to the Luster et al. [5] data in
the current model. The paired data [4] suggest, however, that the
model may underestimate the difference and generate an overly
conservative estimate. For instance, some hypothyroid patients
Figure 3 Other sensitivity analysis.
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may not return to work at all in the period between thyroidec-
tomy and ablation. This would further improve the value of
rhTSH.
The modeled economic evaluation relied upon translation of
SF-36 trial data to utilities using the SF-6D method [19]. There is
a potential bias in using this method because of the “ﬂoor effect,”
which restricts possible utility estimates such that they cannot lie
below 0.3. In this case, however, this is unlikely to be problematic
given that the utility weights of the health states included in the
model are well above this threshold. It could be reasonably
expected, therefore, that the “ﬂoor effect” has not had an impact
on the estimates used. Unfortunately, no alternative utility esti-
mates, such as EQ-5D for example, were available to test the
potential impact of the SF-36 data on the ﬁnal cost-effectiveness
results. It would not be expected, however, that estimates derived
via an alternative methodology would alter the conclusions
drawn.
The model presented the incremental cost-effectiveness asso-
ciated with exogenously stimulated preparation for ablation
using rhTSH in the context of Canada. The method represents a
departure from the earlier, longer-term model [17], as extrapo-
lation of the model to account for a theoretical reduction in
secondary malignancies had no impact on the conclusions
drawn. The model captured all the measurable beneﬁts of rhTSH
in the ablative setting nonetheless. Unquantiﬁable beneﬁts
offered by the greater ﬂexibility of ablation scheduling offered by
rhTSH and possibly a lessening of acute radiation effects on
salivary and lacrimal function resulting from the lower radiation
exposure with rhTSH are not included in the model. Addition-
ally, some of the more salient clinical beneﬁts previously reported
[17], for which more data are required, remain outside the scope
of the model. Additional to these, the model could beneﬁt from
future research on the relative merits of rhTSH with respect to
productivity loss in the ablative setting and the duration of time
spent in the radio-protective ward. Although these were esti-
mated in the best way possible, controlled, head-to-head data
would be ideal. It is not expected, however, that inclusion or
improvement of any of these factors would alter the conclusion
of rhTSH’s value for money in Canada.
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